GUD

Knight Therapeut

• Dow Jones·11/11 17:16

  Correction to Knight Therapeutics 3Q Rev Headline on Nov. 6

• Dow Jones·11/11 16:32

  Profound Medical Regains Distribution Rights for Tulsa-Pro Medical Device System

• Dow Jones·11/06 12:44

  *Knight Therapeutics Raises FY25 View To Rev C$430M-C$440M >GUD.T

• Dow Jones·11/06 12:42

  *Correct: Knight Therapeutics 3Q Rev C$121,548 >GUD.T

• Dow Jones·11/06 12:41

  *Knight Therapeutics Increased 2025 Fincl Guidance >GUD.T

• Dow Jones·11/06 12:31

  *Knight Therapeutics 3Q Loss/Shr C$0.04 >GUD.T

• Dow Jones·11/06 12:31

  *Knight Therapeutics 3Q Rev C$121.5M >GUD.T

• Dow Jones·08/20 12:15

  Knight Therapeutics Gets Exchange Approval for Share Buyback Program

• Dow Jones·08/20 11:31

  *Knight Therapeutics to Buy Back Up to 3M Co. Common Shares Under NCIB >GUD.T

• Dow Jones·08/20 11:30

  *Knight Therapeutics Announces Normal Course Issuer Bid >GUD.T

• Dow Jones·08/07 11:37

  *Knight Therapeutics Increases 2025 Fincl Guidance

• Dow Jones·05/09 15:44

  Knight Therapeutics Inc. Price Target Is Maintained at C$6.50/Share by Canaccord Genuity

• Dow Jones·05/09 15:44

  Knight Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

• Dow Jones·05/08 11:40

  *Knight Therapeutics Backs 2025 Rev C$390M-C$405M >GUD.T

• Dow Jones·05/08 11:39

  *Knight Therapeutics Reconfirmed Its Fincl Guidance Targets for 2025 >GUD.T